Satyanarayana Medicherla

Summary

Affiliation: Schering-Plough Research Institute
Country: USA

Publications

  1. ncbi request reprint Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling
    Sum Yee Leung
    National Heart and Lung Institute, Dovehouse St, London SW3 6LY, UK
    J Pharmacol Exp Ther 319:586-94. 2006
  2. ncbi request reprint A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss
    Keith L Kirkwood
    Department of Periodontics and Oral Medicine, University of Michigan, 1011 N University Ave, Ann Arbor, MI 48109 1078, USA
    J Pharmacol Exp Ther 320:56-63. 2007
  3. ncbi request reprint p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation
    Satyanarayana Medicherla
    Scios Inc, Fremont, California, USA
    J Pharmacol Exp Ther 324:921-9. 2008
  4. pmc Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig
    Satyanarayana Medicherla
    Scios Inc, Fremont, CA, USA
    J Inflamm Res 3:9-16. 2010
  5. ncbi request reprint p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma
    Satyanarayana Medicherla
    Scios Inc, Fremont, CA 94555, USA
    Anticancer Res 28:3827-33. 2008
  6. ncbi request reprint Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment
    Satyanarayana Medicherla
    Scios Inc, Fremont, CA 94555, USA
    Anticancer Res 27:4149-57. 2007
  7. ncbi request reprint Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness
    Nicholas J Gaspar
    Scios Inc, Fremont, CA, USA
    Mol Pharmacol 72:152-61. 2007
  8. ncbi request reprint Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes
    Satyanarayana Medicherla
    Scios Inc, 6500 Paseo Padre Parkway, Fremont, CA 94555, USA
    J Pharmacol Exp Ther 318:99-107. 2006
  9. doi request reprint Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase
    Bruce Koppelman
    Scios, Inc, Fremont, Calif, USA
    Pharmacology 81:204-20. 2008
  10. ncbi request reprint Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation
    Aaron N Nguyen
    Scios Inc, 6500 Paseo Padre Parkway, Fremont, CA 94555, USA
    Exp Cell Res 312:1909-23. 2006

Collaborators

  • Ann M Kapoun
  • Nicholas J Gaspar
  • G David Roodman
  • Judy Anderson
  • Mary F Fitzgerald
  • Noriyoshi Kurihara
  • Keith L Kirkwood
  • Ying Zhang
  • Sarah M Sweitzer
  • A Niimi
  • K Fan Chung
  • Leonidas C Platanias
  • Linda S Higgins
  • Jing Ying Ma
  • Andrew A Protter
  • Aaron N Nguyen
  • Sum Yee Leung
  • Li Zhou
  • Bruce Koppelman
  • Tony A Navas
  • Jill E Rogers
  • Puneeta Nath
  • Kian Fan Chung
  • Alistair Noble
  • Partha Neogi
  • Davendra Sohal
  • Andrea Pellagatti
  • Yu Wang Liu
  • Markus Bitzer
  • Heather K Webb
  • Babu J Mavunkel
  • Sundeep Dugar
  • Amittha Wickrema
  • Ira Braunchweig
  • Aaron Nguyen
  • Jose Carlos Chavez
  • Josh Hayman
  • Krishna Gundabolu
  • Ramona Almirez
  • Bhaskar Das
  • Yongkai Mo
  • Tushar D Bhagat
  • Perry Pahanish
  • Don W Lim
  • Gladys Muiru
  • Cheng Ping Mao
  • Simrit Parmar
  • Suman Kambhampati
  • Gregory Luedtke
  • Irene Kerr
  • Adam Chubak
  • Amit Verma
  • Yuanying Anne Huang
  • Ying Feng
  • Ruban Mangadu
  • Alan F List
  • Jacqueline Boultwood
  • Sarvajit Chakravarty
  • Fei Li
  • Jodie Otremba
  • Jaclynn M Kriegl
  • T Andrew A Protter
  • Derek D Coatney
  • Timothy Oates
  • Jing Y Ma
  • Sundeep Dugar Sarvajit Chakravarty
  • Elizabeth G Stebbins
  • Alison S Williams
  • Edwin Haghnazari
  • Alison Williams
  • Margaret Henson
  • Sun J Choi
  • Andrew Protter
  • Diana Quon
  • Gilbert O'Young
  • George F Schreiner
  • Mamatha Reddy
  • Debby Damm
  • Gregory R Luedtke
  • Andy Protter
  • Jin Cheng
  • Fredrick J Lakner
  • Somesh D Sharma
  • Coleman Gross
  • Debendranath Dey
  • Maya Gowri
  • Lesley B Pickford
  • Bishwajit Nag

Detail Information

Publications18

  1. ncbi request reprint Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling
    Sum Yee Leung
    National Heart and Lung Institute, Dovehouse St, London SW3 6LY, UK
    J Pharmacol Exp Ther 319:586-94. 2006
    ..Inhibition of TGF-betaRI kinase activities by SD-208 may be a useful approach to the reversal of BHR and to the prevention and reversal of inflammatory and remodeling features of chronic asthma...
  2. ncbi request reprint A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss
    Keith L Kirkwood
    Department of Periodontics and Oral Medicine, University of Michigan, 1011 N University Ave, Ann Arbor, MI 48109 1078, USA
    J Pharmacol Exp Ther 320:56-63. 2007
    ..Results from this in vivo study suggest that orally active p38 MAPK inhibitors can reduce LPS-induced inflammatory cytokine production and osteoclast formation and protect against LPS-stimulated alveolar bone loss...
  3. ncbi request reprint p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation
    Satyanarayana Medicherla
    Scios Inc, Fremont, California, USA
    J Pharmacol Exp Ther 324:921-9. 2008
    ....
  4. pmc Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig
    Satyanarayana Medicherla
    Scios Inc, Fremont, CA, USA
    J Inflamm Res 3:9-16. 2010
    ..These observations suggest that α-selective p38 MAPK inhibition may be an effective therapeutic strategy to manage acute skin inflammation...
  5. ncbi request reprint p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma
    Satyanarayana Medicherla
    Scios Inc, Fremont, CA 94555, USA
    Anticancer Res 28:3827-33. 2008
    ..In conclusion, p38 inhibitors reduced human myeloma cell growth in vivo both at early and advanced phases of the disease. The current study also provides evidence of potential for co-therapy with dexamethasone...
  6. ncbi request reprint Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment
    Satyanarayana Medicherla
    Scios Inc, Fremont, CA 94555, USA
    Anticancer Res 27:4149-57. 2007
    ..Taken together, our results indicate that a TGF-betaRI kinase inhibitor has a potential therapeutic benefit for pancreatic cancer patients...
  7. ncbi request reprint Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness
    Nicholas J Gaspar
    Scios Inc, Fremont, CA, USA
    Mol Pharmacol 72:152-61. 2007
    ..Moreover, they suggest that inhibition of TGFbetaRI with a small-molecule inhibitor may be effective as a therapeutic approach to treat human pancreatic cancer...
  8. ncbi request reprint Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes
    Satyanarayana Medicherla
    Scios Inc, 6500 Paseo Padre Parkway, Fremont, CA 94555, USA
    J Pharmacol Exp Ther 318:99-107. 2006
    ....
  9. doi request reprint Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase
    Bruce Koppelman
    Scios, Inc, Fremont, Calif, USA
    Pharmacology 81:204-20. 2008
    ..SD-282 represents a valuable tool to elucidate the role of p38 MAP kinase in multiple models of inflammation...
  10. ncbi request reprint Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation
    Aaron N Nguyen
    Scios Inc, 6500 Paseo Padre Parkway, Fremont, CA 94555, USA
    Exp Cell Res 312:1909-23. 2006
    ..Collectively, these results suggest that SCIO-469 treatment can suppress factors in the bone marrow microenvironment to inhibit MM cell proliferation and adhesion and also to alleviate osteolytic activation in MM...
  11. ncbi request reprint A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis
    Satyanarayana Medicherla
    Scios Inc, 6500 Paseo Padre Parkway, Fremont, CA 94555, USA
    J Pharmacol Exp Ther 318:132-41. 2006
    ..Thus, in a model of experimental arthritis associated with significant osteolysis, p38alpha MAPK inhibition not only attenuates disease progression but also reverses cartilage and bone destruction in mice with advanced CIA disease...
  12. pmc p38 MAPK inhibition reduces diabetes-induced impairment of wound healing
    Satyanarayana Medicherla
    Scios Inc, Fremont, CA, USA
    Diabetes Metab Syndr Obes 2:91-100. 2009
    ..These results suggest a novel approach to prophylactic and therapeutic management of chronic wounds associated with diabetes or other conditions in which healing is impaired...
  13. pmc Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma
    Jing Ying Ma
    Scios Inc, Fremont, CA, USA
    J Asthma Allergy 1:31-44. 2008
    ..These findings suggest that the p38α-selective MAPK inhibitor may have dual therapeutic potential in attenuating both the inflammatory component and the fibrotic component of asthma and other Th2-polarized inflammatory lung diseases...
  14. pmc Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS
    Li Zhou
    Albert Einstein College of Medicine, Bronx, NY, USA
    Blood 112:3434-43. 2008
    ..These data directly implicate TGF-beta signaling in the pathobiology of ineffective hematopoiesis and identify TBRI as a potential therapeutic target in low-risk MDS...
  15. ncbi request reprint A p38 mitogen-activated protein kinase inhibitor arrests active alveolar bone loss in a rat periodontitis model
    Jill E Rogers
    Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109 1078, USA
    J Periodontol 78:1992-8. 2007
    ..The aim of this study was to determine whether the novel, orally active p38 MAPK inhibitor SD282 could arrest progression of LPS-induced alveolar bone destruction in rats...
  16. ncbi request reprint Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness
    Puneeta Nath
    National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK
    Eur J Pharmacol 544:160-7. 2006
    ..Furthermore, bronchial hyperresponsiveness induced by chronic allergen exposure may be related to the development of airway wall remodelling...
  17. ncbi request reprint Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model
    Sarah M Sweitzer
    Department of Anesthesia, Stanford University School of Medicine, Stanford, CA 94305 5117, USA
    Pain 109:409-19. 2004
    ..These results indicate a potential therapeutic value of p38alpha MAPK inhibitors in the treatment of aberrant pain sensitivity produced by diabetes...
  18. ncbi request reprint Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents
    Partha Neogi
    Department of Chemistry, Calyx Therapeutics Inc, 3513 Breakwater Avenue, Hayward, CA 94545, USA
    Bioorg Med Chem 11:4059-67. 2003
    ..Results of pharmacokinetic, metabolism and permeability studies are consistent with 11 being an active prodrug with an active metabolite, 14, that has similar glucose lowering and PPAR gamma agonist properties...